1. Home
  2. GALT vs TECX Comparison

GALT vs TECX Comparison

Compare GALT & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

N/A

Current Price

$2.90

Market Cap

397.3M

Sector

Health Care

ML Signal

N/A

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

N/A

Current Price

$21.25

Market Cap

413.3M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GALT
TECX
Founded
2000
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.3M
413.3M
IPO Year
2008
2018

Fundamental Metrics

Financial Performance
Metric
GALT
TECX
Price
$2.90
$21.25
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $71.00
AVG Volume (30 Days)
★ 185.4K
161.7K
Earning Date
11-16-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
36.84
★ 40.70
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.03
$16.77
52 Week High
$7.13
$39.53

Technical Indicators

Market Signals
Indicator
GALT
TECX
Relative Strength Index (RSI) 35.26 46.32
Support Level $2.78 $20.52
Resistance Level $3.30 $22.95
Average True Range (ATR) 0.30 1.30
MACD -0.03 0.24
Stochastic Oscillator 5.13 54.40

Price Performance

Historical Comparison
GALT
TECX

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: